Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine

Transplant International

Volumn 12, Issue 4, 1999, Pages 283-287

  Meisel, Helga ^a   Preikschat, Petra ^a   Reinke, Petra ^a   Hocher, Berthold ^a   Budde, Klemens ^a   Bechstein, Wolf Otto ^a   Neuhaus, Peter ^a   Krüger, Detlev H ^a   Neumayer, Hans H ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Combined kidney liver transplantation; Famciclovir; Hepatitis B core deletion mutants; Kidney transplantation; Lamivudine

Indexed keywords

ANTIVIRUS AGENT; FAMCICLOVIR; HEPATITIS B SURFACE ANTIGEN; HYPERIMMUNE GLOBULIN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CASE REPORT; DELETION MUTANT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS REPLICATION;

2-AMINOPURINE; ANTIVIRAL AGENTS; DNA, VIRAL; FOLLOW-UP STUDIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LAMIVUDINE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUTATION; RENAL DIALYSIS; SEQUENCE DELETION; VARIATION (GENETICS);

EID: 0032884888     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001470050225     Document Type: Article

References (11)

1. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P (1997) Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 26: 1148-1153
2. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Coudreay LD, Tzakis AG, Schiff ER, Brown NA (1997) Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349: 20-22
3. Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kaspa R (1997) Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 63: 393-396
4. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, Tubiana R, Herson S, Poynard T, Opolon P (1996) Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 125: 705-712
5. Dienstag JL, Perillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333: 1657-1661
6. Günther S, Baginski S, Kissel H, Reinke P, Krüger DH, Will H, Meisel H (1996) Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease. Hepatology: 24: 751-758
7. Günther S, Piwon N, Iwanska A, Schilling R, Meisel H, Will H (1996) Type, prevalence and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. J Virol 70: 8318-8331
8. Haller GW, Bechstein WO, Neuhaus R, Raakow R, Berg T, Hopf U, Neuhaus P (1996) Famciclovir therapy for recurrent hepatitis B virus infection after liver transplantation. Transplant Int 9 [Suppl 1]: S210-S212
9. Honkoop P, Niesters HGM, Deman RAM, Osterhaus ADME, Schalm SW (1997) Lamivudine resistance in immunocompetent chronic hepatitis B: Incidence and patterns. J Hepatol 26: 1393-1395
10. Klein M, Geoghehan J, Schmidt K, Bockler D, Korn K, Wittekind C, Scheele J (1997) Conversion of recurrent Delta positive hepatitis B infection to seronegative with famciclovir after liver transplantation. Transplantation 64: 162-163
11. Singh N, Gayowski, Wannstedt DF, Wagener MM, Marino IR (1997) Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 63: 1415-1419